Contract manufacturer Life Science Outsourcing, Inc. (LSO) announced Thursday it had acquired medical manufacturing, packaging, and sterilization outsourcing company J-Pac Medical.
The deal will expand LSO’s reach into the biomaterials and diagnostics end markets, the company said, as well as broaden its service offerings and secure its production capabilities on the East Coast and in Costa Rica.
“J-Pac Medical stood out as a unique and attractive business that aligned perfectly with LSO’s strategic and commercial objectives,” said John Nino, CEO of LSO. “The company’s capabilities in reagent blister packaging, thermoforming, and biomaterials will be additive to LSO’s existing customer base. J-Pac Medical’s assembly, packaging and sterilization capabilities are complimentary to LSO, and both will be strengthened by this truly synergistic alliance.”
LSO is a leading medical device contract manufacturer registered with the FDA. The ISO 13485 certified company offers clients services from cleanroom assembly to packaging, sterilization, medical device manufacturing, and medical package testing, and more. J-Pac Medical has more than 35 years of experience in manufacturing anatomically correct, class III implantable textile assemblies, lab-on-chip reagent blisters, and complicated thermoformed packaging. J-Pac operates a 60,000-square-foot ISO 13485 certified and FDA-registered facility in New Hampshire.
“J-Pac Medical’s technical know-how and production experience around reagent blister packaging in the molecular diagnostics end-market represents an exciting growth opportunity given trends in point-of-care diagnostics, specifically as it relates to microfluidics and lab-on-a-chip applications,” said Jeff Barrett, President of the newly formed Diagnostics Division. “Our partnership with LSO broadens our reach within the life sciences and diagnostics end-markets we are targeting.”
LSO was acquired by PPC Enterprises, a New York-based private equity firm investing in a select group of industries, including industrial services and health care services, in January 2021. The acquisition of J-Pac would build on PPC’s vision for LSO to grow into a national platform for post-manufacturing and regulated services to “early-stage and established players in the growing med-tech and diagnostics end-markets.”